2024-04-19  10:58:09 PM Chg. +0.150 Volume Bid10:58:09 PM Ask10:58:09 PM Market Capitalization Dividend Y. P/E Ratio
31.750EUR +0.47% -
Turnover: -
31.750Bid Size: - 32.300Ask Size: - 1.73 bill.EUR 2.74% 27.67

Business description

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Management board & Supervisory board

CEO
Dr. Hans-Georg Feldmeier
Management board
Dr. Andreas Eberhorn, Christof Dreibholz
Supervisory board
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Company data

Name: Dermapharm Holding SE
Address: Lil-Dagover-Ring 7,D-82031 Grünwald
Phone: +49-89-64186-0
Fax: +49-89-64186-130
E-mail: -
Internet: ir.dermapharm.de/index.php
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: -
IPO date: 2018-02-09

Investor relations

Name: Britta Hamberger
IR phone: +49-89-64186-233
IR Fax: +49-89-64186-165
IR e-mail: ir@dermapharm.com

Company calendar

CW 23 | 2024-06-06 Ex-Dividend
CW 23 | 2024-06-07 Record Date
CW 24 | 2024-06-10 Dividend Payment
CW 26 | 2024-06-27 General Shareholder Meeting
CW 35 | 2024-08-27 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Themis Beteiligungs-AG
 
68.50%
free float
 
31.50%